Browse our anti-ESM1 (ESM1) Antibodies

Mouse (Murine) Endothelial Cell-Specific Molecule 1 (ESM1) interaction partners

1. Data from murine model indicate that NGFR plays an important role in the pathogenesis and progression of oral squamous cell carcinoma via regulation of ESM1.

2. glomerular-derived Esm-1 as a potential non-invasive biomarker of diabetic nephropathy

3. Results reveal a novel pathway for endocan in the control of tumor growth, which involves inflammatory cells of the innate immunity.

4. Esm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability.

5. This study shows endocan can elicit severe inflammatory responses and inhibiting endocan release offers a potential strategy for treating sepsis.

6. endocan is normally present in the mouse brain and prior vascular perfusion with FITC may provide a useful tool for identify newly forming blood vessels.

7. Mouse endocan serum level was measured at a median of 0.96 ng/mL and 1.08 ng/mL in 129Sv mice and C57bl6, respectively.

8. A paracrine vasoregulatory pathway mediated by endothelial cell-derived ET-1 acting on the vascular smooth muscle ET(A) receptor.

9. Results suggest that endocan (ESM-1)is preferentially expressed in tumor endothelium in vivo and that its expression is regulated by tumor-derived factors.

Human Endothelial Cell-Specific Molecule 1 (ESM1) interaction partners

1. endocan levels are higher in patients who require mechanical ventilation in severe sepsis

2. Results show that aerum ESM-1 levels were significantly higher in the idiopathic sudden sensorineural hearing loss group than the control group which may confirm endothelial dysfunction involvement.

3. suggest that measurement of endocan level may help clinicians to predict the development of coronary collateral circulation in patients with stable coronary artery disease

4. suggest that serum ESM-1 level may be a novel endothelial dysfunction biomarker

5. Plasma ESM-1 levels are decreased during pregnancy and increased in early- and late-onset preeclampsia. The source of ESM-1 is probably not the placenta, but most likely maternal endothelial cells.

6. Serial endocan concentration meets the major requirements for predicting outcome in patients with severe sepsis. An assay of endocan concentration may be a good prognostic biomarker in the clinic for severe sepsis.

7. The cutoff serum level of endocan predicting AD was >288.94 ng/mL in receiver operating characteristic curve analysis

8. A strong negative correlation was found between serum endocan levels and peak systolic velocity in men with severe erectile dysfunction.

9. Results show the endocan level in peripheral blood significantly elevated in patients newly diagnosed with multiple myeloma (MM), and associated with myeloma-specific clinical parameters.

10. The correlation between the secretion of endocan and that of IL-6 by endothelial cells suggests that endocan can be used as a predictive marker of inflammation for the quality assessment of transfusion grade PLTs

11. Serum ESM-1 levels correlate with stress hyperglycemia in patients with STEMI and are associated with short-term prognosis.

12. Endocan could be a common predictor of the endothelium-dependent inflammatory processes, rather than related with specific risk factors in coronary artery disease and microvascular angina.

13. Endocan is an inflammatory marker released by the endothelium and is associated with endothelial dysfunction and atherosclerosis in patients with systemic lupus erythematosus.

14. Endocan levels are higher in patients with large-artery atherosclerotic stroke and can help in predicting the short-term unfavourable outcome.

15. elevated expression on epidermal keratinocytes and dermal endothelial cells in lesional skin of atopic dermatitis; decreased expression in atopic dermatitis sera

16. Plasma ESM-1 is a novel biomarker for predicting the T status in OSCC patients.

17. ESM1 expression correlates with Gleason grade/score and with androgen receptor expression in prostate carcinoma tissue, so ESM1 should also be considered as a biomarker for diagnosis of prostate cancer.

18. Demonstrate an increased Endocan serum level in NAFLD patients, higher in those with type 2 diabetes mellitus and/or NASH because of an endothelial dysfunction in these pathologies.

19. Studied serum endocan levels in endometrial and ovarian cancer. Serum endocan levels were significantly higher in the entire patient group than in the controls.

20. This study showed that ESM-1 level in pleural effusion could be a potential diagnostic and prognostic marker in NSCLC patients with MPE.